Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small‐Cell Lung Cancer Models
Cancer Science · 2026-11 · 117 (11) · 2997-3006
DOI: 10.1111/cas.70486 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 28.07.2026. Verfasst von Kyoji Tsurumi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori, Japan. Hauptthemen laut MEDLINE: Nicotinamide Phosphoribosyltransferase, Small Cell Lung Carcinoma, Lung Neoplasms, Cytokines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Science and Technology Agency, Ministry of Education, Culture, Sports, Science and Technology, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Small‐cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. We previously showed that nicotinic acid riboside (NAR) sustains NAD biosynthesis in vivo and compensates for NAMPT inhibition in SCLC models. Here, we evaluated combining NAMPT inhibition with dietary nicotinic acid (NA) restriction to suppress NAR‐dependent NAD biosynthesis. This combination showed enhanced antitumor activity consistent with synthetic lethality in SCLC CDX models and showed robust efficacy in PDX models, including those derived from chemotherapy‐refractory tumors. In most CDX models examined, combination therapy showed greater antitumor activity than standard chemotherapy with cisplatin and etoposide. Although we did observe transient leukopenia, the treatment was otherwise better tolerated than chemotherapy, with less impact on body weight and platelet counts. These findings support NAD metabolism–targeted therapy as a promising strategy to treat SCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori, Japan.
- Department of Biochemical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Respiratory Medicine, Miyagi Cancer Center Hospital, Natori, Japan.
- Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.
- Human Biology-Microbiome-Quantum Research Center, Keio University, Tsuruoka, Japan.
ORCID-Profile: Shigehiro Yagishita, Nobuhiro Tanuma
Förderung
- Japan Science and Technology Agency
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
- Princess Takamatsu Cancer Research Fund
- Takeda Foundation
- Naito Foundation
Zitieren
APA
Tsurumi, K., Nomura, M., Ouchi, M., Yagishita, S., Kikuchi, N., Sato, T., Morita, M., Yamashita, Y., Hayashi, K., Soga, T., Hamada, A., Fukuhara, T., & Tanuma, N. (2026). Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small‐Cell Lung Cancer Models. Cancer Science, 117(11), 2997-3006. https://doi.org/10.1111/cas.70486
Vancouver
Tsurumi K, Nomura M, Ouchi M, Yagishita S, Kikuchi N, Sato T, et al. Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small‐Cell Lung Cancer Models. Cancer Science. 2026;117(11):2997-3006. doi:10.1111/cas.70486
BibTeX
@article{Tsurumi2026,
author = {Tsurumi, Kyoji and Nomura, Miyuki and Ouchi, Mai and Yagishita, Shigehiro and Kikuchi, Naohiko and Sato, Taku and Morita, Mami and Yamashita, Yoji and Hayashi, Kayoko and Soga, Tomoyoshi and Hamada, Akinobu and Fukuhara, Tatsuro and Tanuma, Nobuhiro},
title = {Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small‐Cell Lung Cancer Models},
journal = {Cancer Science},
year = {2026},
volume = {117},
number = {11},
pages = {2997--3006},
doi = {10.1111/cas.70486}
}
EUVIMED